Quantcast
Last updated on April 18, 2014 at 15:19 EDT

SkinVet Introduces RESPIT Oromucosal Spray, Breaking Down Barriers to Allergy Treatment for Pets

June 4, 2012

LOS ANGELES, June 4, 2012 /PRNewswire/ — Allergies have been especially severe this year for people and for pets. Fifteen to twenty percent of all dogs suffer from an allergy to pollens, mold spores, and dust mites, resulting in an itchy skin condition called atopic dermatitis. A number of treatment modalities are available to treat these pets, but only one targets the source and can change the underlying disease process: allergy immunotherapy. Most pets with atopic dermatitis do not receive allergy immunotherapy due to two previous requirements: (1) having the pet allergy tested, and (2) the need for frequent, long-term injections.

Now, SkinVet(TM) has introduced prescription solutions that break down both barriers, making allergy immunotherapy available to many more allergic pets. RESPIT(TM) Oromucosal Spray brings together the concepts of sublingual immunotherapy (SLIT) and SkinVet’s patent-pending process of geographic region-specific immunotherapy formulation. Pets receive two to three squirts per day inside the cheek, where allergens are absorbed and processed by the mucosal immune system to induce tolerance to the common offending allergens. More information is available at http://www.vetrespit.com.

“The feedback we have received on RESPIT and the Oromucosal Spray has been phenomenal,” says Jon Plant, DVM, board-certified veterinary dermatologist and founder of SkinVet. “Veterinarians who take a moment to learn about RESPIT understand that it is a practical approach to immunotherapy that makes sense to them and their clients.”

Contact

Jon Plant, DVM, DACVD
SkinVet®
15800 SW Upper Boones Ferry Rd. #120
Lake Oswego, OR 97035
503-352-3376
jon.plant@skinvetclinic.com
http://www.vetrespit.com

This press release was issued through eReleases® Press Release Distribution. For more information, visit http://www.ereleases.com.

SOURCE SkinVet Clinic


Source: PR Newswire